Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Lyme disease - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

Lyme disease

MONDO:0019632

Also known as:Bannwarth syndromeBannworth's syndromeBorrelia

Find Clinical TrialsTrials

Overview

Lyme disease (named after the towns in the USA where the disease was first identified) is a bacterial infection caused by Borrelia burgdorferi.

Clinical Trials36 registered · 19 recruiting

Patient Orgs1 organizations · LymeDisease.org

Diagnosis

Biomarker and diagnostic research for Lyme disease has been reported in the published literature.

Prognosis

Estimated prevalence: Unknown (Unknown prevalence).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

36 clinical trials registered, 19 recruiting. Interventions under study include other interventions, medical devices, drug therapy, and biologic therapy. Pipeline includes 3 PHASE4, 3 PHASE3, 3 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT06611111](https://clinicaltrials.gov/study/NCT06611111)

Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 11:53 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Patient Support

Patient Advocacy Groups

View all PAGs →

LymeDisease.orgPrimary Focus

USWebsite ↗

Patient Registry

Enroll Now

Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.

Are you a patient organization not listed here? Claim this page to be listed and embed this content on your site — free.

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:91546

Questions for Your Care Team

→Are any of the 36 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→How can I connect with LymeDisease.org and other patient organizations for support?

← Back to All Diseases

Research Type	Count	% of Total
Disease patterns and progression	89	29%
Laboratory research	75	24%
Research summaries	60	19%
Testing and diagnosis research	26	8%
Patient case studies	26	8%
Clinical study results	18	6%
New treatment approaches	14	5%
Other research	3	1%

Latest News & Developments

5 recent

View all

AI-curated news mentioning Lyme disease

Updated Mar 23, 2026

BioPharma Dive•

Pipeline & Approvals

•6 months ago(Mar 23)

Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results

Pfizer and Valneva plan to seek approval for their Lyme disease vaccine, reporting 'clinically meaningful' efficacy despite not meeting the primary study objective due to a lower-than-expected infection rate. This move highlights their commitment to addressing Lyme disease amidst mixed trial results.

BioSpace•

Pipeline & Approvals

•6 months ago(Mar 23)

Pfizer ‘Confident’ in Valneva-Partnered Lyme Vaccine Despite Missed Primary Endpoint

Pfizer remains confident in its Lyme disease vaccine developed with Valneva, despite missing a primary endpoint in Phase 3 trials. The vaccine demonstrated over 73% efficacy against Lyme disease, indicating potential for future development.

Pharma Times•

Pipeline & Approvals

•8 months ago(Feb 2)

En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation

En Carta Diagnostics' EC Pocket Lyme test has received FDA Breakthrough Device Designation, aiming to improve diagnosis for the approximately 476,000 new Lyme disease cases reported annually in the US. This designation may expedite the test's development and review process.

CDC Newsroom•

Policy & Access

•8 months ago(Jan 23)

Lyme Disease Vaccine

Clinical trials for new Lyme disease vaccines are currently underway, but no vaccine is available yet. This highlights ongoing efforts to address Lyme disease prevention amid rising cases.

Congress.gov Health Bills•

Policy & Access

•about 1 year ago(Aug 15, 2025)

HR 4981: Stamp Out Lyme Disease Act

The Stamp Out Lyme Disease Act (HR 4981) has been referred to the Committee on Oversight and Government Reform and the Committee on Energy and Commerce for further consideration. This bill aims to address issues related to Lyme disease, although specific provisions are yet to be determined.

View all news for Lyme disease

Lyme disease

Overview

Diagnosis

Prognosis

Research Landscape

Patient Support

Patient Advocacy Groups

Medical References

External Resources

Orphanet

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Recent Publications

Latest News & Developments

Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results

Pfizer ‘Confident’ in Valneva-Partnered Lyme Vaccine Despite Missed Primary Endpoint

En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation

Lyme Disease Vaccine

HR 4981: Stamp Out Lyme Disease Act